NeuBase Therapeutics Inc (NBSE)
NASDAQ (CM) NASDAQ (CM) Primary Summary
NBSE Chart
NeuBase Therapeutics Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 David Einhorn Greenlight Capital Re Ltd. | 136,350 | $254,975 | $51,540.3 | -$203,434.7 | -79.79% |
NeuBase Therapeutics Inc (NBSE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NeuBase Therapeutics Inc ever had a stock split?
NeuBase Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Todd P. Branning CEO | NASDAQ (CM) Exchange | 64132K201 CUSIP |
| US Country | 37 Employees | - Last Dividend | 4 Feb 2019 Last Split | 1 May 2007 IPO Date |
Overview
NeuBase Therapeutics, Inc. is at the forefront of biopharmaceutical innovation, focusing on the development of ground-breaking therapies designed to combat rare genetic diseases and cancers sparked by mutant genes. Operating from its headquarters in Pittsburgh, Pennsylvania, the company is currently in the preclinical stage, channeling its efforts towards leveraging its proprietary technology to bring hope and potentially life-altering treatments to patients under the heavy burden of genetic disorders and cancer. By targeting the root cause of these diseases—mutant genes—NeuBase strives to make significant strides in areas where the medical need is huge but yet inadequately addressed.
Products and Services
- NT0100 for Huntington's Disease
NeuBase's NT0100 project is a pioneering therapeutic venture aimed at tackling Huntington's disease (HD), a devastating genetic disorder characterized by the progressive breakdown of nerve cells in the brain. Employing the company's advanced PATrOL platform, NT0100 seeks to provide a targeted, novel approach to mitigate the symptoms and potentially alter the course of this currently incurable disease.
- NT0200 for Myotonic Dystrophy Type 1
The NT0200 development project is tailored to address myotonic dystrophy type 1, which stands as the most common form of muscular dystrophy affecting adults worldwide. This product leverages the PATrOL technology to disrupt the disease's progression by targeting the genetic abnormalities at their core, offering hope for improved life quality for those affected by this condition.
- NT0300 for Mutated KRAS Gene
Taking aim at cancer, NeuBase’s NT0300 treatment zeros in on the mutated KRAS gene—a notorious contributor to various cancers. Through its innovative approach, NT0300 holds the promise of a targeted therapy that could significantly impact the management of cancers driven by KRAS mutations. This represents a critical step forward in oncology, considering the KRAS mutation's role in many hard-to-treat cancers.
